CT-P17 (N = 324) | EU-adalimumab (N = 324) | |
---|---|---|
Age (years), median (range) | 53.5 (18–75) | 54.0 (19–75) |
Sex, n (%) | ||
Male | 75 (23.1) | 59 (18.2) |
Female | 249 (76.9) | 265 (81.8) |
Race, n (%) | ||
White | 299 (92.3) | 298 (92.0) |
Mestizo | 24 (7.4) | 26 (8.0) |
Native Peruvian | 1 (0.3) | 0 |
Ethnicity, n (%) | ||
Hispanic or Latino | 29 (9.0) | 34 (10.5) |
Non-Hispanic or non-Latino | 295 (91.0) | 290 (89.5) |
RA disease duration (years), mean (SD) | 6.79 (6.76) | 6.59 (6.81) |
SDAI at screening, n (%) | ||
SDAI ≤ 26 | 30 (9.3) | 34 (10.5) |
SDAI > 26 | 294 (90.7) | 290 (89.5) |
SDAI, mean (SD) | 40.0 (11.5) | 39.8 (11.1) |
CDAI, mean (SD) | 39.0 (11.0) | 38.7 (10.8) |
DAS28-CRP, mean (SD) | 5.538 (0.8738) | 5.547 (0.8525) |
Tender joint count, mean (SD) | 20.5 (10.2) | 20.1 (10.1) |
Swollen joint count, mean (SD) | 14.0 (6.33) | 14.0 (6.46) |
Subject’s assessment of pain, mean (SD)a | 69.7 (18.7) | 70.0 (16.2) |
Subject’s global assessment of disease activity, mean (SD)a | 69.8 (17.8) | 69.6 (16.3) |
Physician’s global assessment of disease activity, mean (SD)a | 67.5 (14.7) | 67.0 (15.5) |
HAQ estimate of physical ability, mean (SD) | 1.41 (0.59) | 1.48 (0.56) |
CRP (mg/dl), mean (SD) | 0.975 (1.60) | 1.10 (1.91) |
ESR (mm/h), mean (SD) | 42.3 (15.98) | 42.9 (16.94) |